ACM
GILD icon

Advisors Capital Management’s Gilead Sciences GILD Stock Holding History

Advisors Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4M Buy
31,697
+1,373
+5% +$181K 0.04% 242
2026
Q1 		$4.23M Sell
30,324
-390
-1% -$54.6K 0.05% 221
2025
Q4 		$3.77M Buy
30,714
+147
+0.5% +$17.9K 0.04% 237
2025
Q3 		$3.39M Buy
30,567
+127
+0.4% +$14.4K 0.04% 240
2025
Q2 		$3.37M Sell
30,440
-5,755
-16% -$612K 0.05% 230
2025
Q1 		$4.06M Sell
36,195
-2,968
-8% -$306K 0.06% 206
2024
Q4 		$3.62M Buy
39,163
+654
+2% +$58.9K 0.06% 216
2024
Q3 		$3.23M Buy
38,509
+26,180
+212% +$2M 0.05% 221
2024
Q2 		$846K Sell
12,329
-4,916
-29% -$328K 0.01% 305
2024
Q1 		$1.26M Buy
17,245
+4,029
+30% +$310K 0.02% 272
2023
Q4 		$1.07M Buy
13,216
+421
+3% +$32.8K 0.02% 283
2023
Q3 		$959K Buy
12,795
+843
+7% +$64.8K 0.02% 258
2023
Q2 		$921K Sell
11,952
-137
-1% -$10.9K 0.02% 261
2023
Q1 		$1M Buy
12,089
+204
+2% +$16.9K 0.03% 248
2022
Q4 		$1.02M Sell
11,885
-735
-6% -$58.2K 0.03% 251
2022
Q3 		$1.05M Buy
12,620
+2,755
+28% +$174K 0.03% 255
2022
Q2 		$610K Sell
9,865
-1,350
-12% -$83.6K 0.02% 282
2022
Q1 		$667K Sell
11,215
-42
-0.4% -$2.69K 0.02% 279
2021
Q4 		$817K Buy
11,257
+11
+0.1% +$758 0.02% 275
2021
Q3 		$786K Sell
11,246
-136
-1% -$9.55K 0.02% 268
2021
Q2 		$784K Buy
11,382
+552
+5% +$36.9K 0.02% 256
2021
Q1 		$699K Sell
10,830
-203
-2% -$13.1K 0.02% 247
2020
Q4 		$642K Sell
11,033
-76
-0.7% -$4.59K 0.02% 246
2020
Q3 		$702K Sell
11,109
-263
-2% -$18.2K 0.03% 203
2020
Q2 		$875K Buy
11,372
+765
+7% +$58.6K 0.04% 181
2020
Q1 		$793K Buy
10,607
+1,335
+14% +$92.2K 0.05% 179
2019
Q4 		$602K Buy
+9,272
New +$604K 0.03% 245

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Advisors Capital Management's GILD Position: Q2 2026 in Review

Advisors Capital Management increased its Gilead Sciences (GILD) stake by 4.5% in Q2 2026, buying an estimated $181K and bringing the position to 31,697 shares worth $4M. The position accounts for 0.04% of the portfolio, ranked #242.

Advisors Capital Management first reported a position in GILD in Q4 2019 and has held it in 27 quarters since. The position peaked at $4.23M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Advisors Capital Management held 31,697 shares of Gilead Sciences worth $4M as of Q2 2026.
  • Advisors Capital Management bought 1,373 Gilead Sciences shares in Q2 2026, an estimated $181K.
  • Gilead Sciences made up 0.04% of Advisors Capital Management's portfolio in Q2 2026, its #242 holding.
  • Advisors Capital Management first reported a position in Gilead Sciences in Q4 2019 and has held it in 27 quarters since.
  • Advisors Capital Management's Gilead Sciences position peaked at $4.23M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Advisors Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.